Author Archives: Patrick Gilbert

Manufactured by Jetting: The Future in Protein A Affinity Matrix Design

by , , and

Protein A affinity chromatography continues to be the preferred method for commercial purification of antibodies because of its high selectivity and robust resin performance over repeated purification cycles. Reports estimate that US$125 billion of yearly sales will be generated from monoclonal antibody (MAb) products by 2020 (1). Most of those will be purified by largescale protein A affinity chromatography. With the continued growth and commercial importance of MAb production, availability of high-quality resin material and options for secondary sourcing are…

December 11, 2018

New Agarose-Based Protein A Resins Designed for Cost Effective Purification of MAbs

by , , , , , and

It is well recognized that the cost of Protein A resins is substantial. If a product makes it to marketing approval and manufacturing the high cost is amortized over a large number of purification cycles then the contribution to cost of goods is acceptable. However, a high percentage of clinical projects will fail and the Protein A resin will only be used for a small number of cycles. One way to address this issue is to use a less expensive…

December 20, 2016

Decreasing Cost of Clinical Trials Through the Use of Two Novel Protein A Resins

by , , , , and

Tackling the High Cost of Protein A in Early Clinical Phases The cost of Protein A resins is very high, commonly 5-10 times higher compared to standard chromatography resins. One way to address this issue is to use a less expensive Protein A resin during early clinical trials, where the risk of failure is higher and fewer cycles are run, and subsequently switch to a resin designed for manufacturing if the product makes it to PIII and beyond. The higher…

March 18, 2016

A Fresh Approach to Process and Cost Efficiencies in Early Clinical and Biosimilars Production

by , , , , and

This poster will introduce Praestoâ„¢ AC protein A resin and ProcessReady pre-packed columns from Purolite. Platform processes for MAbs manufacturing have long been used to save time and costs. The use of highly productive, cost- effective resins in such platforms can magnify these savings, and the addition of ready-to use formats can further enhance process efficiencies. Our approach is to maximize these efficiencies and cost savings in early clinical-phase production and in the manufacture of biosimilars by using stage-appropriate materials…

November 19, 2015

Modern Resins for a MAb Platform Process

by , , , , and

Purolite is using new technologies to produce homogeneous beaded agarose for protein purification at large scale. Particle sizes range from 40 to 90 μm. The resins cover applications from capture to polishing and demonstrate improved pressure–flow properties (Figure 1). The porosity structure is optimized for medium-sized proteins such as monoclonal antibodies (MAbs). Read the full text of this application note in the PDF (Login required).

August 18, 2015